Rational design of novel N‐alkyl amine analogues of noscapine, their chemical synthesis and cellular activity as potent anticancer agents

  title={Rational design of novel N‐alkyl amine analogues of noscapine, their chemical synthesis and cellular activity as potent anticancer agents},
  author={Rajesh Kumar Meher and Pratyush Pragyandipta and Ravi Kumar Pedapati and Praveen K R Nagireddy and Srinivas Kantevari and Arnab Nayek and Pradeep K Naik},
  journal={Chemical Biology \& Drug Design},
  pages={445 - 465}
The scaffold structure of noscapine (an antitussive plant alkaloid) was modified by inducting N‐aryl methyl pharmacophore at C‐9 position of the isoquinoline ring to rationally design and screened three novel 9‐(N‐arylmethylamino) noscapinoids, 15–17 with robust binding affinity with tubulin. The selected 9‐(N‐arylmethylamino) noscapinoids revealed improved predicted binding energy of −6.694 kcal/mol for 15, −7.118 kcal/mol for 16 and −7.732 kcal/mol for 17, respectively in comparison to the… 
1 Citations


In silico design of novel tubulin binding 9-arylimino derivatives of noscapine, their chemical synthesis and cellular activity as potent anticancer agents against breast cancer.
9-arylimino derivatives of noscapine have great potential to be a novel therapeutic agent for breast cancers and effectively inhibit proliferation of cancer cells, arrest the cell cycle in the G2/M-phase and induced apoptosis.
Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents
The newly designed noscapinoid, 5e is an orally bioavailable, safe and effective anticancer agent with a potential for the treatment of cancer and might be a candidate for clinical evaluation.
Rational Design, Synthesis, and Biological Evaluation of Third Generation α-Noscapine Analogues as Potent Tubulin Binding Anti-Cancer Agents
The study reported here identified potent, third generation noscapinoids as new anti-cancer agents that perturbed DNA synthesis, delayed the cell cycle progression at G2/M phase, and induced apoptotic cell death in cancer cells.
Synthesis and biological evaluation of novel biaryl type α-noscapine congeners.
Second generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluation.
Rational Design of Novel Anti-microtubule Agent (9-Azido-Noscapine) from Quantitative Structure Activity Relationship (QSAR) Evaluation of Noscapinoids
To obtain systematic insight into the relationship between the structural framework of noscapine scaffold and its antitumor activity, the authors synthesized strategic derivatives (including two new ones in this article) that turned out to be very close to predicted pIC50.
Rational design of 9-vinyl-phenyl noscapine as potent tubulin binding anticancer agent and evaluation of the effects of its combination on Docetaxel
A novel concept of combination treatment of DOX and VPN to amend efficiency in breast cancer treatment is provided and the dose dependent cytotoxicity ofDOX has been reduced considerably with the combination dose regimen of VPN.
Development of a Novel Nitro-Derivative of Noscapine for the Potential Treatment of Drug-Resistant Ovarian Cancer and T-Cell Lymphoma
9-nitro-nos has great potential to be a novel therapeutic agent for ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs.
Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid
The ‘blind docking’ approach as well as the reasonable accuracy of calculating ΔGbind using LIE–SGB model constitutes the first evidence that this class of compounds binds to tubulin at a site overlapping with colchicine-binding site or close to it.
In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin)
Chemical synthesis, tubulin-binding experiments, and anti-cancer activity in vitro corroborate fully well with the molecular modelling experiments.